μ-Opioid receptor ligands lack receptor subtype selectivity in the aequorin luminescence-based calcium assay

Chemical Biology and Drug Design

Volumn 70, Issue 3, 2007, Pages 247-253

  Fichna, Jakub ^a   Staniszewska, Renata ^a   Poels, Jeroen ^b   Broeck, Jozef Vanden ^b   Janecka, Anna ^a  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

^b UNIVERSITY OF LEUVEN   (Belgium)

Author keywords

opioid receptor selective antagonist; Endomorphins; In vitro functional assay

Indexed keywords

AEQUORIN; CALCIUM; ENDOMORPHIN 1; ENDOMORPHIN 2; ENKEPHALIN[2 DEXTRO ALANINE 4 METHYLPHENYLALANINE 5 GLYCINE]; MU OPIATE RECEPTOR; NALOXONAZINE; NALOXONE;

ANIMAL CELL; ANTINOCICEPTION; ARTICLE; BIOASSAY; CALCIUM CELL LEVEL; CHINESE HAMSTER; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFECT; DRUG SELECTIVITY; FEMALE; IC 50; IN VITRO STUDY; IN VIVO STUDY; LUMINESCENCE; NONHUMAN; OVARY CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION;

AEQUORIN; ANIMALS; CALCIUM; CHO CELLS; CRICETINAE; CRICETULUS; LIGANDS; LUMINESCENT MEASUREMENTS; RECEPTORS, OPIOID, MU; SENSITIVITY AND SPECIFICITY; SUBSTRATE SPECIFICITY;

CRICETULUS GRISEUS;

EID: 34548156243     PISSN: 17470277     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1747-0285.2007.00550.x     Document Type: Article

References (43)

1. Wolozin B.L., Pasternak G.W. (1981) Classification of multiple morphine and enkephalin binding sites in the central nervous system. Proc Natl Acad Sci U S A 78 : 6181 6185.
2. Moskowitz A.S., Goodman R.R (1985) Autoradiographic distribution of Mu1 and Mu2 opioid binding in the mouse central nervous system. Brain Res 360 : 117 129.
3. Hahn E.F., Carroll-Buatti M., Pasternak G.W. (1982) Irreversible opiate agonist and antagonists: the 14-hydroxydihydromorphine azines. J Neurosci 2 : 572 576.
4. Ling G.S.F., Simantov R., Clark J.A., Pasternak G.W. (1986) Naloxonazine actions in vivo. Eur J Pharmacol 129 : 33 38.
5. Sakurada S., Zadina J.E., Kastin A.J., Katsuyama S., Fujimura T., Murayama K., Yuki M., Ueda H., Sakurada T. (1999) Differential involvement of μ-opioid receptor subtypes in endomorphin-1- and -2-induced antinociception. Eur J Pharmacol 372 : 25 30.
6. Sakurada S., Takeda S., Sato T., Hayashi T., Yuki M., Kutsuwa M., Tan-No K., Sakurada C., Kisara K., Sakurada T. (2000) Selective antagonism by naloxonazine of antinociception by Tyr-D-Arg-Phe-β-Ala, a novel dermorphin analogue with high affinity at μ-opioid receptors. Eur J Pharmacol 395 : 107 112.
7. Sato T., Sakurada S., Takahashi N., Sakurada T., Tan-No K., Wako K., Kisara K. (1999) Contribution of spinal μ1-opioid receptors to morphine-induced antinociception. Eur J Pharmacol 369 : 183 187.
8. Bodnar R.J., Williams C.L., Lee S.J., Pasternak G.W. (1988) Role of m1-opiate receptors in supraspinal opiate analgesia: a microinjection study. Brain Res 47 : 25 34.
9. Mann P.E., Arjune D., Romero M.-T., Pasternak G.W., Hahn E.F., Bodnar R.J. (1988) Differential sensitivity of opioid-induced feeding to naloxone and naloxonazine. Psychopharmacology 94 : 336 341.
10. Simone D.A., Bodnar R.J., Goldman E.J., Pasternak G.W. (1985) Involvement of opioid receptor subtypes in rat feeding behaviour. Life Sci 36 : 829 833.
11. Suzuki T., Hayashi Y., Misawa M. (1992) The role of μ1 receptor in physical dependence on morphine using the m receptor deficient CXBK mouse. Life Sci 50 : 849 856.
12. Wood P.L., Rich J.W. (1982) Morphine and nigrostriatal function in the rat and mouse: the role of nigral and striatal opiate receptors. Neuropharmacology 21 : 1305 1310.
13. Ling G.S.F., Spiegel K., Lockhart S.H., Pasternak G.W. (1985) Separation of opioid analgesia from respiratory depression: evidence for different receptor mechanisms. J Pharmacol Exp Ther 232 : 149 155.
14. Zadina J.E., Hackler L., Ge L.J., Kastin A.J. (1997) A potent and selective endogenous agonist for the mu-opiate receptor. Nature 386 : 499 502.
15. Sakurada S., Hayashi T., Yuhki M., Fujimura T., Murayama K., Yonezawa A., Sakurada C., Takeshita M., Zadina J.E., Kastin A.J., Sakurada T. (2000) Differential antagonism of endomorphin-1 and endomorphin-2 spinal antinociception by naloxonazine and 3-methoxynaltrexone. Brain Res 881 : 1 8.
16. Narita M., Ozaki S., Ioka M., Mizoguchi H., Nagase H., Tseng L.F., Suzuki T. (2001) Lack of the involvement of m1-opioid receptor subtype on motivational effects induced by the endogenous μ-opioid receptor ligands endomorphin-1 and -2 in the mouse. Neurosci Lett 308 : 17 20.
17. 2 discriminate different μ-opioid receptor mediated antinociception in mice. Br J Pharmacol 137 : 1143 1146.
18. 2-opioid receptor antagonist in the mouse. J Pharmacol Exp Ther 312 : 1075 1081.
19. 2-endomorphin-2, respectively, attenuate the antinociception induced by endomorphin-1 and endomorphin-2 given intrathecally in the mouse. J Pharmacol Exp Ther 303 : 874 879.
20. Fichna J., do-Rego J.C., Costentin J., Chung N.N., Schiller P.W., Kosson P., Janecka A. (2004) Opioid receptor binding and in vivo antinociceptive activity of position 3-substituted morphiceptin analogs. Biochem Biophys Res Commun 320 : 531 536.
21. Fichna J., do-Rego J.-C., Costentin J., Janecka A. (2005) Characterization of antinociceptive activity of novel endomorphin-2 and morphiceptin analogs modified in the third position. Biochem Pharmacol 69 : 179 185.
22. Fichna J., Gach K., Piestrzeniewicz M., Burgeon E., Poels J., Vanden Broeck J., Janecka A. (2006) Functional characterization of opioid receptor ligands by aequorin luminescence-based calcium assay. J Pharmacol Exp Ther 317 : 1150 1154.
23. 4]endomorphin-2 (Antanal-2). J Med Chem 50 : 512 520.
24. Stables J., Green A., Marshall F., Fraser N., Knight E., Sautel M., Milligan G., Lee M., Rees S. (1997) A bioluminescent assay for agonist activity at potentially any G-protein-coupled receptor. Anal Biochem 252 : 115 126.
25. Tseng L.F., Narita M., Suganuma C., Mizoguchi H., Ohsawa M., Nagase H., Kampine J.P. (2000) Differential antinociceptive effects of endomorphin-1 and endomorphin-2 in the mouse. J Pharmacol Exp Ther 292 : 576 583.
26. Elliott J., Smart D., Lambert D.G., Traynor J.R. (1994) Characterisation of mu-opioid receptors on SH-SY5Y cells using naloxonazine and beta-funaltrexamine. Eur J Pharmacol 268 : 447 450.
27. Harrison L.M., Kastin A.J., Zadina J.E. (1998) Differential effects of endomorphin-1, endomorphin-2, and Tyr-W-MIF-1 on activation of G-proteins in SH-SY5Y human neuroblastoma membranes. Peptides 19 : 749 753.
28. Hosohata K., Burkey T.H., Alfaro-Lopez J., Varga E., Hruby V.J., Roeske W.R., Yamamura H.I. (1998) Endomorphin-1 and endomorphin-2 are partial agonists at the human mu-opioid receptor. Eur J Pharmacol 346 : 111 114.
29. Toll L. (1990) Mu-opioid receptor binding in intact SH-SY5Y neuroblastoma cells. Eur J Pharmacol 176 : 213 217.
30. Bare L.A., Mansson E., Yang D. (1994) Expression of two variants of the human mu-opioid receptor mRNA in SK-N-SH cells and human brain. FEBS Lett 354 : 213 216.
31. Zimprich A., Simon T., Hollt V. (1995) Cloning and expression of an isoform of the rat mu-opioid receptor (rMOR1B) which differs in agonist induced desensitization from rMOR1. FEBS Lett 359 : 142 146.
32. Pan Y.X., Xu J., Bolan E., Abbadie C., Chang A., Zuckerman A., Rossi G., Pasternak G.W. (1999) Identification and characterization of three new alternatively spliced μ-opioid receptor isoforms. Mol Pharmacol 56 : 396 403.
33. Pan Y.X., Xu J., Bolan E., Chang A., Mahurter L., Rossi G., Pasternak G.W. (2000) Isolation and expression of a novel alternatively spliced mu opioid receptor isoform MOR-1 F. FEBS Lett 466 : 337 340.
34. Bouvier M. (2001) Oligomerization of G-protein-coupled transmitter receptors. Nat Rev Neurosci 2 : 274 286.
35. George S.R., O'Dowd B.F., Lee S.P. (2002) G-protein-coupled receptor oligomerization and its potential for drug discovery. Nat Rev Drug Discov 1 : 808 820.
36. Milligan G. (2004) G protein-coupled receptor dimerization: function and ligand pharmacology. Mol Pharmacol 66 : 1 7.
37. George S.R., Fan T., Xie Z., Tse R., Tam V., Varghese G., O'Dowd B.F. (2000) Oligomerization of mu- and delta-opioid receptors. Generation of novel functional properties. J Biol Chem 275 : 26128 26135.
38. Gomes I., Jordan B.A., Gupta A., Trapaidze N., Nagy V., Devi L.A. (2000) Heterodimerization of mu and delta opioid receptors: a role in opiate synergy. J Neurosci 20 : 1 5.
39. Martin N.A., Prather P.L. (2001) Interaction of co-expressed mu- and delta-opioid receptors in transfected rat pituitary GH(3) cells. Mol Pharmacol 59 : 774 783.
40. Parkhill A.L., Bidlack J.M. (2002) Several δ-opioid receptor ligands display no subtype selectivity to the human δ-opioid receptor. Eur J Pharmacol 451 : 257 264.
41. Shane R., Wilk S., Bodnar R.J. (1999) Modulation of endomorphin-2-induced analgesia by dipeptidyl peptidase iv. Brain Res 815 : 278 286.
42. Paterlini M.G., Avitabile F., Ostrowski B.G., Ferguson D.M., Portoghese P.S. (2000) Stereochemical requirements for receptor recognition of the μ-opioid peptide endomorphin-1. Biophys J 78 : 590 599.
43. 2, and examination of their opioid receptor binding activities and solution conformation. Biochem Biophys Res Commun 276 : 7 11.